STOCK TITAN

Bristol-Myers Squibb Co. - BMY STOCK NEWS

Welcome to our dedicated news page for Bristol-Myers Squibb Co. (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bristol-Myers Squibb Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bristol-Myers Squibb Co.'s position in the market.

Rhea-AI Summary
New data shows positive outcomes for Zeposia in treating relapsing multiple sclerosis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
-
Rhea-AI Summary
Bristol Myers Squibb to acquire Mirati for $4.8 billion in cash
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
-
Rhea-AI Summary
Paradigm collaborates with Bristol Myers Squibb to build a new clinical trial operating model
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
Rhea-AI Summary
Bristol Myers Squibb (BMY) will announce Q3 2023 results on October 26, 2023. Investors can join the conference call and webcast. Materials available at http://investor.bms.com. Replay available until November 9, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
conferences earnings
-
Rhea-AI Summary
Bristol Myers Squibb's Phase 3 trial shows improved event-free survival in non-small cell lung cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
-
News
Rhea-AI Summary
Bristol Myers Squibb declares quarterly dividends on common and preferred stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
dividends
Rhea-AI Summary
Samsung Biologics announces new agreement with Bristol Myers Squibb for large-scale manufacturing of a commercial antibody cancer drug substance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) expects to double the number of registrational assets from six to 12 over the next 18 months. The company's Cell Therapy and Targeted Protein Degradation platforms offer potential for expanding treatment options across multiple therapeutic areas. Bristol Myers Squibb aims to drive top-tier productivity through its enhanced approach to R&D.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
-
Rhea-AI Summary
Bristol Myers Squibb announces six-year results from Phase 3 trial demonstrating long-term survival benefits of Opdivo plus Yervoy in metastatic non-small cell lung cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
Rhea-AI Summary
Bristol Myers Squibb announces positive results from Phase 2 study on BMS-986278 in patients with progressive pulmonary fibrosis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

BMY Stock Data

97.81B
2.02B
0.1%
78.93%
1.73%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About BMY

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.